| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada |
|
Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
